DTCFF
Price:
$0.41395
Market Cap:
$26.19M
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in...[Read more]
Industry
Biotechnology
IPO Date
2021-05-18
Stock Exchange
PNK
Ticker
DTCFF
According to Defence Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.88. This represents a change of -79.63% compared to the average of -9.23 of the last 4 quarters.
The mean historical PE Ratio of Defence Therapeutics Inc. over the last ten years is -9832.83. The current -1.88 PE Ratio has changed -98.09% with respect to the historical average. Over the past ten years (40 quarters), DTCFF's PE Ratio was at its highest in in the December 2023 quarter at -2.89. The PE Ratio was at its lowest in in the December 2019 quarter at -9836.28.
Average
-9832.83
Median
-44.57
Minimum
-58719.80
Maximum
-3.01
Discovering the peaks and valleys of Defence Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 72.88%
Maximum Annual PE Ratio = -3.01
Minimum Annual Increase = -99.70%
Minimum Annual PE Ratio = -58719.80
Year | PE Ratio | Change |
---|---|---|
2024 | -3.01 | -81.90% |
2023 | -16.62 | 72.88% |
2022 | -9.61 | -86.75% |
2021 | -72.53 | -58.66% |
2020 | -175.42 | -99.70% |
The current PE Ratio of Defence Therapeutics Inc. (DTCFF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-9.75
5-year avg
-55.44
10-year avg
-9832.83
Defence Therapeutics Inc.’s PE Ratio is less than Sino Biopharmaceutical Limited (16.30), less than Institute of Biomedical Research Corp. (-0.08), greater than Aileron Therapeutics, Inc. (-3.16), less than Enlivex Therapeutics Ltd. (-1.14), less than Panbela Therapeutics, Inc. (-0.06), less than Lixte Biotechnology Holdings, Inc. (-1.09), greater than Benitec Biopharma Inc. (-2.02), less than Cingulate Inc. (-1.18), less than TRACON Pharmaceuticals, Inc. (0.02), greater than XOMA Corporation (-19.71), less than Fortress Biotech, Inc. (-0.70), greater than Checkpoint Therapeutics, Inc. (-3.00), greater than ZIVO Bioscience, Inc. (-4.35), less than Lumos Pharma, Inc. (-1.00), less than Apellis Pharmaceuticals, Inc. (0), greater than Terns Pharmaceuticals, Inc. (-10.63), greater than Day One Biopharmaceuticals, Inc. (-5.51), greater than Blueprint Medicines Corporation (-17.12), greater than Cerevel Therapeutics Holdings, Inc. (-45.48), greater than null (-17.73),
Company | PE Ratio | Market cap |
---|---|---|
16.30 | $8.30B | |
-0.08 | $9.60M | |
-3.16 | $86.66M | |
-1.14 | $27.83M | |
-0.06 | $1.80M | |
-1.09 | $4.39M | |
-2.02 | $214.00M | |
-1.18 | $11.66M | |
0.02 | $136.30K | |
-19.71 | $355.58M | |
-0.70 | $47.68M | |
-3.00 | $154.67M | |
-4.35 | $68.83M | |
-1.00 | $35.87M | |
0 | $3.48B | |
-10.63 | $599.50M | |
-5.51 | $1.49B | |
-17.12 | $5.84B | |
-45.48 | $8.19B | |
-17.73 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Defence Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Defence Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Defence Therapeutics Inc.'s PE Ratio?
How is the PE Ratio calculated for Defence Therapeutics Inc. (DTCFF)?
What is the highest PE Ratio for Defence Therapeutics Inc. (DTCFF)?
What is the 3-year average PE Ratio for Defence Therapeutics Inc. (DTCFF)?
What is the 5-year average PE Ratio for Defence Therapeutics Inc. (DTCFF)?
How does the current PE Ratio for Defence Therapeutics Inc. (DTCFF) compare to its historical average?